The best ideas happen when the right people work together.
COLLABORATIVE PARTNERS + INVESTMENT PILLARS
Collaboration is at the center of Curebound’s unique grantmaking platform. All Curebound grants demand collaboration among specialized teams from our research partner institutions, enabling the brightest minds from different scientific disciplines to work together to produce better options and outcomes for patients. Curebound'S institutional research partners include:
Curebound funds promising, innovative oncology research for all types of cancer, adult and pediatric, in alignment with five scientific investment pillars:
Curebound funds three levels of cancer research grants. For information on our annual grant cycle and application process, please contact our Grants Department via email@example.com
One-time seed grants of up to $250,000 for high-risk/high-reward, translational research. Ideas are innovative and in the early phases where smaller grants can make a big impact in advancing research.
Larger awards of $500,000 that aim to fund projects that are closer to clinical stages. Targeted Grants require interdisciplinary collaboration in order to ensure the project is geared toward translational application.
Innovative, multi-disciplinary projects that receive major funding of $1,000,000+ to be administered over multiple years. The Cure Prize challenge is to develop an innovation that will improve the standard of care for a typically deadly cancer with patient application in 3-5 years.
Curebound raises and invests strategic funding in translational cancer research projects aimed at accelerating new discoveries to clinical application. The full index of our research portfolio is available below.
Type of Grant
Medulloblastoma is the most common malignant childhood brain tumor. It is a highly heterogeneous cancer, comprising four subgroups: Sonic Hedgehog, Wingless, Group 3, and Group 4. Group 3 MB has the worst prognosis of all Medulloblastomas. Group 3 often exhibits amplification of chromosome 8q24, which contains the potent oncogene MYC.Read More
Neuroblastoma is a tumor of developmental origin with high incidence of metastatic disease at initial diagnosis. Comprehensive DNA sequencing of high-risk neuroblastoma has identified few clinically actionable gene mutations and precision medicine has not benefited most neuroblastoma patients.Read More
Myelodysplastic syndrome (MDS) is a pre-cancer condition involving mutations in the stem cells which give rise to the many cell types which compose blood. These mutations cause stem cells to produce red blood cells and other cell types less efficiently, conditions called cytopenias — complications to which most MDS patients succumb.Read More
One approach to treating tumors uses intravenous therapies that help the immune system. This works in many cancers, however, this approach does not always work, and can fail with time as tumors find ways to avoid the immune system – even shutting off its ability to attack tumors.Read More
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a 5-year survival rate of 11%. Most patients die within 6 months of diagnosis from metastatic disease, but even patients who qualify for surgical resection eventually succumb to the disease. No targeted therapies are available.Read More
Brain and other tumors of the central-nervous system (CNS) are the most common cancers in children aged 0- 14 years in the USA. Ependymoma (EPN) is the third most common pediatric brain tumor and a leading cause of death in childhood cancer patients.Read More
Neuroblastoma is a cancer that accounts for more than 15% of all childhood cancer deaths. Despite multimodal therapy, the 5-year survival rate of children with high-risk disease is very low. Hence, novel, and safe therapies are needed to combat this childhood cancer. Here, we propose a targeted strategy to improve the effectiveness of anti-cancer therapy for this childhood cancer.Read More
Hundreds of thousands of years ago, before humans evolved from primates, another pandemic caused by viruses occurred. This pandemic was caused by retroviruses, which are viruses that can insert their own genetic information into the DNA of their hosts.Read More
One in six men will be diagnosed with prostate cancer (PCa), making it one of the leading health problems affecting men in today’s society. Patients diagnosed during the earlier stages are surviving longer due to improved therapies and the prevalence of prostate-specific antigen (PSA) testing.Read More
The Cure Prize is Curebound’s highest award for bold innovation in cancer research, recognizing Innovative, multi-disciplinary projects that receive major funding of $1,000,000+ to be administered over multiple years. The first Cure Prize challenge was to develop an innovation that will improve the standard of care for a typically deadly cancer with patient application in 3-5 years.
In June, 2022 Curebound awarded its first Cure Prize:
2023 Cure Prize: Screening for Ovarian Cancer with Advanced Diffusion MRI in Patients at High Risk for Ovarian Cancer
In Honor of the Koman Family
Scientists: Rebecca Rakow-Penner MD, PhD, Anders Dale, PhD, Michael McHale, MD (UC San Diego)
Ovarian cancer is the fifth-most deadly cancer in women in the United States with 60% of cases already metastasized at the time of diagnosis. Multiple screening programs have been attempted, but none so far have demonstrated survival benefit. This project, led by the brilliant team of doctors Rakow-Penner, Dale and McHale at UC San Diego, will develop a robust screening technique, based on advanced diffusion-weighted MRI, that can non-invasively image ovarian cancers. This will decrease the need for surgical removal of ovaries from at risk women while offering the promise of novel screening technique for early detection and treatment for all women.
“Our project, my passion, is to develop an innovative and advanced MRI protocol specifically tailored to detecting ovarian cancer in its earliest stages. By harnessing the power of cutting-edge technology, we aim to provide the information to at risk women so they can make informed decisions about their health and specifically about the very difficult decision they face with respect to prophylactic surgery. With the support of Curebound, we aim to significantly improve the outcomes for women facing this formidable challenge.”
- Rebecca Rakow-Penner, MD, PhD
UC San Diego Health